Tempest Therapeutics Inc. reported financial results for the second quarter and Six months ended June 30, 2021. For the quarter, the company's Operating loss was USD 6,785,000 against USD 5,238,000 a year ago. Net loss was USD 7,058,000 against USD 5,229,000 a year ago. Net loss per share was USD 7.63 against USD 11.42 a year ago. For the Six months, the company's Operating loss was USD 11,912,000 against USD 9,541,000 a year ago. Net loss was USD 12,413,000 against USD 9,457,000 a year ago. Net loss per share was USD 17.30 against USD 21.28 a year ago.